Last updated: September 9, 2026
Pexidartinib hydrochloride, marketed as Turalio by Daiichi Sankyo, is a specialty oncology drug for adults with symptomatic tenosynovial giant cell tumor, or TGCT, when surgery is unlikely to provide acceptable functional benefit. The drug has a narrow commercial market, significant liver-monitoring requirements, and limited indication breadth. Its revenue trajectory has been positive but modest relative to Daiichi Sankyo’s broader oncology portfolio.
The market changed materially in February 2025 when Deciphera Pharmaceuticals received FDA approval for vimseltinib, marketed as Romvimza, creating the first direct approved commercial competitor in TGCT. Pexidartinib retains clinical differentiation through its established use and broad CSF1R pathway activity, but its hepatotoxicity profile and REMS requirements increase switching and prescribing friction.
What is pexidartinib hydrochloride used for?
Pexidartinib is an oral small-molecule inhibitor of colony-stimulating factor 1 receptor, or CSF1R, KIT, and FLT3. Its primary commercial use is TGCT, a rare tumor involving the synovium, bursae, or tendon sheaths.
The FDA indication covers adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. The approved dose is 250 mg twice daily with a low-fat meal, delivered as two 125 mg capsules per dose.[1]
TGCT is a rare condition. The addressable population is constrained by:
- Low disease prevalence.
- A high proportion of patients managed surgically or through observation.
- Concentration of treatment in specialist sarcoma and orthopedic oncology centers.
- The requirement that patients have severe morbidity or functional limitation.
- The availability of a competing CSF1R inhibitor.
Pexidartinib is not approved for broad solid-tumor treatment, rheumatoid arthritis, or other inflammatory diseases. Its financial performance therefore depends on penetration within a focused orphan-drug market rather than expansion across large oncology categories.
When did the FDA approve Turalio, and what regulatory restrictions apply?
The FDA approved Turalio on Aug. 2, 2019, under the accelerated approval pathway based primarily on overall response rate and duration of response in patients with TGCT.[2]
The principal regulatory constraint is hepatotoxicity. The drug carries a boxed warning for serious and potentially fatal liver injury. Turalio is distributed through a Risk Evaluation and Mitigation Strategy, or REMS, that requires:
- Prescriber enrollment.
- Pharmacy certification.
- Patient enrollment and counseling.
- Baseline liver testing.
- Frequent liver-function monitoring during treatment.
- Dose interruption, reduction, or discontinuation based on laboratory findings.
The REMS directly affects market adoption. It raises administrative costs for prescribers, complicates dispensing, and can make a competing drug with less intensive monitoring more attractive even where efficacy is comparable.
FDA regulatory milestones
| Date |
Event |
| 2015-2016 |
FDA orphan-drug designation and development in TGCT |
| Aug. 2, 2019 |
FDA approval of Turalio |
| 2019 |
U.S. commercial launch by Daiichi Sankyo |
| 2021-2023 |
Continued postmarketing safety monitoring and REMS implementation |
| Feb. 14, 2025 |
FDA approval of vimseltinib, the first direct approved competitor |
The FDA approval was based on the ENLIVEN study, which showed clinically meaningful tumor response and improvement in tumor-related symptoms in appropriate patients.[3]
How large is the pexidartinib and TGCT market?
The TGCT market is an orphan oncology market with high treatment value per patient but limited patient volume. Publicly reported Turalio sales indicate gradual commercial growth rather than a rapid blockbuster trajectory.
Daiichi Sankyo reports Turalio sales in Japanese yen. Reported annual revenue has remained small compared with the company’s total pharmaceutical sales.
| Fiscal year ending March 31 |
Reported Turalio sales, approximately |
| FY2020 |
¥0.6 billion |
| FY2021 |
¥1.5 billion |
| FY2022 |
¥2.7 billion |
| FY2023 |
¥3.5 billion |
| FY2024 |
Approximately ¥4 billion to ¥5 billion |
Sources: Daiichi Sankyo annual reports and financial-results materials.[4-7]
This pattern indicates a compound annual growth rate well above 50% from the first commercial year through FY2024, but from a small base. Turalio remains a subscale product for Daiichi Sankyo. With Daiichi Sankyo annual revenue above ¥1 trillion, Turalio contributes well below 1% of consolidated sales.
The product’s commercial profile is therefore defined by high orphan-drug pricing, long treatment duration in responders, and low patient volume. The largest revenue opportunities are not broad population expansion but better diagnosis, earlier treatment, international commercialization, and retention of patients who would otherwise undergo repeated surgery or receive observation.
What is driving pexidartinib revenue growth?
Turalio revenue growth has several identifiable drivers.
Increasing specialist adoption
Initial uptake was slowed by the REMS, COVID-era disruptions, and the need to educate orthopedic oncologists and sarcoma specialists. As more clinicians gained experience managing liver monitoring, use expanded in specialized treatment centers.
Treatment of unresectable disease
Turalio addresses patients whose disease is diffuse, recurrent, or located near critical structures. These patients may have limited surgical options and a greater willingness to use systemic therapy.
Persistent treatment duration
Patients who respond and tolerate pexidartinib can remain on therapy for extended periods. A treatment model based on ongoing therapy is more valuable than a one-time intervention, although toxicity-driven discontinuation limits persistence.
Orphan-drug economics
Pexidartinib carries specialty-drug economics, including high per-patient revenue and concentrated dispensing. The model depends on reimbursement rather than large unit volumes.
International opportunity
U.S. approval established the core commercial franchise. International revenue remains constrained by local approvals, reimbursement, and the availability of surgery. The U.S. is likely to remain the principal market because of its specialist infrastructure and orphan-oncology pricing.
How does pexidartinib compare with vimseltinib?
Vimseltinib is the most important competitive development for Turalio. Deciphera’s Romvimza was approved by the FDA in February 2025 for adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.[8]
| Attribute |
Pexidartinib |
Vimseltinib |
| Brand |
Turalio |
Romvimza |
| Company |
Daiichi Sankyo |
Deciphera Pharmaceuticals |
| Target |
CSF1R, KIT, FLT3 |
CSF1R |
| Route |
Oral |
Oral |
| TGCT approval |
2019 |
2025 |
| Key safety issue |
Serious hepatotoxicity |
Liver monitoring remains relevant, but commercial positioning emphasizes a different safety and dosing profile |
| Distribution burden |
REMS |
No equivalent Turalio-style commercial barrier publicly central to the product’s positioning |
| Market role |
Established first entrant |
Direct challenger and category-expansion product |
Vimseltinib can pressure Turalio in three ways:
- New patients may begin on vimseltinib rather than pexidartinib.
- Patients with liver-monitoring concerns may switch away from Turalio.
- Payers may use competition to demand discounts or impose preferred-product rules.
Turalio retains advantages from earlier market entry, physician familiarity, accumulated real-world experience, and an established clinical-response record. The competitive balance will depend on comparative tolerability, dosing convenience, payer contracting, and the extent to which clinicians view the two drugs as interchangeable.
What patent and exclusivity rights protect pexidartinib?
Pexidartinib’s protection is based on a combination of small-molecule patents, pharmaceutical-composition claims, treatment-method claims, and regulatory exclusivity.
The principal protection categories are:
- Pexidartinib chemical-composition patents.
- Salt and crystalline-form claims involving pexidartinib hydrochloride.
- Pharmaceutical formulation and dosage-form claims.
- Methods of treating TGCT and related CSF1R-driven conditions.
- FDA orphan-drug exclusivity.
- Potential patent-term adjustment and patent-term extension, where applicable.
The FDA Orange Book is the controlling public source for patents listed against an approved small-molecule product. Orange Book protection for Turalio should be analyzed separately from orphan exclusivity because the two forms of protection have different legal effects. Orphan exclusivity blocks FDA approval of the same drug for the same indication for seven years, while patents can support infringement litigation against an ANDA applicant and may cover broader chemical or formulation subject matter.[9]
When does pexidartinib lose orphan exclusivity?
Turalio’s seven-year orphan-drug exclusivity is generally calculated from its Aug. 2, 2019 approval date and runs to approximately Aug. 2, 2026, subject to statutory exceptions and the scope of the approved orphan indication.
The expiration of orphan exclusivity does not automatically create generic entry. An ANDA applicant still must address listed patents, demonstrate pharmaceutical equivalence, and overcome any regulatory or litigation barriers.
What is the Paragraph IV risk for Turalio?
A generic applicant could file an ANDA with a Paragraph IV certification alleging that one or more Orange Book-listed patents are invalid, unenforceable, or not infringed. Such a filing could trigger Hatch-Waxman litigation and a potential 30-month stay of FDA approval under applicable conditions.[10]
No publicly established generic launch date should be assumed solely from the orphan-exclusivity expiration. The commercial timing depends on:
- The patents listed in the current Orange Book.
- Patent expiration and pediatric-exclusivity dates.
- The scope of any formulation or method patents.
- Whether a generic applicant files a Paragraph IV certification.
- Whether Daiichi Sankyo initiates litigation.
- Any settlement agreement governing launch.
What manufacturing and intellectual-property barriers affect generic entry?
Pexidartinib is a small molecule, so it does not present the manufacturing complexity of a biologic. The principal barriers are regulatory and intellectual-property barriers rather than cell-line, device, or biologic-process barriers.
Potential entry issues include:
- Reproducing the hydrochloride salt and dosage form.
- Demonstrating bioequivalence under food-effect conditions.
- Managing the product’s low-fat-meal administration requirements.
- Addressing the REMS or any modified shared-system requirements.
- Avoiding formulation patents.
- Avoiding method-of-use patents covering TGCT treatment.
- Obtaining sufficient commercial scale for a low-volume orphan market.
A generic entrant may face a weak volume proposition even after legal clearance. A low patient population, specialist distribution, monitoring requirements, and incumbent contracting can limit the economic value of entry.
Which companies are challenging pexidartinib commercially?
The main direct competitor is Deciphera Pharmaceuticals with vimseltinib. Before vimseltinib’s approval, competition came primarily from non-drug treatment options and off-label systemic therapy.
| Competitor or alternative |
Commercial status |
Impact on Turalio |
| Vimseltinib/Romvimza |
FDA-approved in 2025 |
Direct product competition |
| Surgery |
Established standard for suitable disease |
Reduces systemic-treatment population |
| Observation |
Used for selected indolent or manageable disease |
Delays drug initiation |
| Imatinib and other off-label agents |
Limited off-label use |
Low-cost alternative in selected cases |
| Emactuzumab and investigational CSF1R agents |
Clinical development or historical development |
Pipeline risk rather than current broad competition |
The market is more likely to divide by patient and physician preference than to expand rapidly through mass substitution. The presence of two approved CSF1R-directed agents may increase diagnosis and treatment of TGCT, but it will also raise payer scrutiny.
What litigation and settlement risks affect Turalio?
Turalio’s principal foreseeable litigation risk is a Hatch-Waxman challenge after generic applicants address Orange Book patents. The relevant litigation questions are:
- Whether a Paragraph IV certification is filed.
- Whether Daiichi Sankyo sues within the statutory period.
- Whether a 30-month stay applies.
- Whether the parties settle and, if so, what launch date is granted.
- Whether the settlement includes authorized-generic or supply provisions.
- Whether method-of-use patents survive validity and infringement challenges.
No specific settlement should be treated as established without a current court docket or SEC filing. The absence of a widely reported generic launch does not prove that patent risk has been eliminated.
What is the revenue exposure for Daiichi Sankyo?
Turalio is strategically relevant but financially immaterial to Daiichi Sankyo’s consolidated results. The company’s major value drivers are its large oncology products, including Enhertu, datopotamab deruxtecan, and other late-stage assets.
| Financial factor |
Effect on Daiichi Sankyo |
| Turalio revenue growth |
Positive but small in absolute terms |
| Orphan pricing |
Supports high revenue per treated patient |
| Limited population |
Caps peak sales |
| REMS and hepatotoxicity |
Restricts penetration and persistence |
| Vimseltinib launch |
Creates direct pricing and volume pressure |
| Generic entry after exclusivity |
Potentially reduces long-term U.S. revenue |
| Manufacturing complexity |
Manageable for a small molecule |
| Strategic value |
Adds an approved specialty-oncology asset and commercial infrastructure |
Turalio is therefore unlikely to become a material driver of Daiichi Sankyo valuation on a standalone basis. Its value is more relevant in portfolio terms: it provides a marketed rare-oncology product, a specialist prescriber network, and cash flow from a niche indication.
What generic launch scenarios exist for pexidartinib?
Three launch scenarios are commercially plausible.
Early authorized or settled entry
Daiichi Sankyo could settle with a first filer and permit entry before the latest patent expiry. This would preserve some value through a negotiated launch while reducing litigation cost.
Patent-protected delay
A Paragraph IV case could result in a 30-month stay, settlement, or trial outcome that delays generic approval. This scenario preserves branded revenue but may generate legal expense and uncertainty.
Multiple-generic erosion after patent expiry
If no enforceable patent blocks approval after orphan exclusivity ends, several ANDA applicants could enter. In a small market, the first generic may capture substantial share, while later entrants accelerate price erosion.
Because TGCT is a low-volume specialty market, unit erosion may be gradual in absolute dollars but sharp as a percentage of Turalio sales.
Key Takeaways
- Pexidartinib hydrochloride is marketed as Turalio for adults with severe, symptomatic TGCT that is not adequately treatable with surgery.
- FDA approval occurred on Aug. 2, 2019, under the accelerated approval pathway.
- The product’s central commercial limitation is serious hepatotoxicity and the associated REMS.
- Reported sales increased from roughly ¥0.6 billion in FY2020 to approximately ¥4 billion to ¥5 billion by FY2024.
- Turalio remains a small contributor to Daiichi Sankyo’s total revenue.
- Vimseltinib, approved in February 2025, is the first direct approved commercial competitor.
- Orphan exclusivity is expected to run approximately through August 2026, while patent protection must be assessed separately through current Orange Book listings.
- Generic entry risk depends on Paragraph IV activity, patent litigation, settlement terms, formulation claims, and method-of-use claims.
- The product’s long-term value is constrained by the small TGCT population and competition from vimseltinib.
FAQs about pexidartinib hydrochloride
Is pexidartinib chemotherapy?
No. Pexidartinib is an oral targeted kinase inhibitor, not a conventional cytotoxic chemotherapy. It inhibits CSF1R and other kinases involved in tumor-associated macrophage signaling.
Does pexidartinib cure tenosynovial giant cell tumor?
The drug is intended to control disease and improve symptoms and function. It is not generally described as a curative treatment. Treatment duration depends on response, tolerability, and the patient’s surgical alternatives.
Why does pexidartinib require liver monitoring?
Pexidartinib can cause severe liver injury, including mixed or cholestatic liver toxicity. The FDA requires structured liver testing and a REMS to reduce this risk.
Is pexidartinib more effective than vimseltinib?
There is no basis for assuming direct superiority from cross-trial response comparisons. Comparative assessment requires head-to-head evidence or carefully adjusted real-world analysis.
Will pexidartinib become available as a generic after 2026?
Not automatically. The end of orphan exclusivity may permit FDA approval of a competing product, but listed patents, Paragraph IV litigation, formulation rights, regulatory requirements, and settlement agreements can delay generic launch.
References
-
U.S. Food and Drug Administration. (2023). Turalio (pexidartinib) prescribing information.
-
U.S. Food and Drug Administration. (2019, August 2). FDA approves first therapy for tenosynovial giant cell tumor.
-
Tap, W. D., Gelderblom, H., Stacchiotti, S., et al. (2019). Efficacy and safety of pexidartinib in advanced tenosynovial giant-cell tumour: An international, double-blind, placebo-controlled, phase 3 trial. The Lancet, 394(10197), 478-487.
-
Daiichi Sankyo Company, Limited. (2021). Annual report 2021.
-
Daiichi Sankyo Company, Limited. (2022). Annual report 2022.
-
Daiichi Sankyo Company, Limited. (2023). Annual report 2023.
-
Daiichi Sankyo Company, Limited. (2024). Annual report 2024.
-
U.S. Food and Drug Administration. (2025, February 14). FDA approves vimseltinib for tenosynovial giant cell tumor.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
